Monoclonal Antibody Treatment for COVID-19

Monoclonal antibody IV treatments help support the immune system to fight a Covid-19 infection.

Monoclonal Antibody IV Therapy

Monoclonal antibodies are lab-created proteins that mimic the immune system’s ability to fight off viruses and diseases. Bebtelovimab is a monoclonal antibody therapy directed against SARS-CoV-2. It is designed to block the virus’ attachment and entry into human cells. Currently, bebtelovimab is the only monoclonal antibody authorized under the FDA’s EUA for the treatment of COVID-19.

The treatment is shown to:

  • Reduce the risk of hospitalization
  • Reduce the severity of symptoms

Price: enter zip below to see local pricing

Who Is Eligible To Receive Monoclonal Antibody IV Therapy?

Monoclonal antibody treatments are available for adults and children who meet certain criteria who:

  • Have tested positive for Covid-19
  • Have mild to moderate symptoms
  • Are at high risk for developing complications
  • Are vaccinated or unvaccinated
  • Are 12 years of age or older weighing at least 88 pounds

Book Monoclonal Antibody IV Therapy

Not ready to book? Contact us here.

Returning customer? Click here to login

Frequently Asked Questions

What are monoclonal antibodies?

Monoclonal antibodies are lab-created proteins that mimic the ones our bodies produce to fight viruses. The antibodies defend the body by blocking Covid-19 viruses from attaching to human cells.

What is Bebtelovimab?

Bebtelovimab, pronounced: beb-te-LOV-i-mab

Bebtelovimab is a neutralizing antibody drug. When there’s a virus in your body such as COVID-19, your immune system makes antibodies to fight it off. But it takes time for your body to make antibodies for a new virus, and in the meantime, you could get very sick. Bebtelovimab contains man-made antibodies designed to help fight the virus. Bebtelovimab does not contain the COVID-19 virus.

Who is not eligible for this treatment?

Bebtelovimab is NOT authorized for use in people who:

  • Are hospitalized due to COVID-19
  • Require oxygen therapy and/or respiratory support due to COVID-19
  • Require an increase in baseline oxygen flow rate and/or respiratory support due to COVID-19 and are on chronic oxygen therapy and/or respiratory support due to an underlying non-COVID-19 related comorbidity

How is Monoclonal Antibody Therapy administered?

Bebtelovimab will be given as an injection through a vein (intravenously or IV) over at least 30 seconds. You will be monitored for at least 1 hour after you receive bebtelovimab.

Where can Drip Hydration administer the treatment?

In order to ensure the safety and comfort of our patients, we offer this treatment in a house call setting.

What are the important possible side effects of bebtelovimab?

The side effects of receiving any medicine intravenously may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the injection site.

Allergic reactions can happen during and after injection with bebtelovimab. You will be monitored for signs of an allergic reaction, including fever, difficulty breathing, low oxygen level in your blood, chills, tiredness, fast or slow heart rate, chest discomfort pain, weakness, confusion, nausea, headache, shortness of breath, low or high blood pressure, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness, feeling faint, and sweating. These reactions may be severe or life threatening.

Is Bebtelovimab FDA approved?

Bebtelovimab has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19 and for whom alternative COVID-19 treatments are not an option.

Do I have to test positive for COVID first?

Yes. Eligibility for Monoclonal Antibody IV Treatment currently requires that you have recently tested positive for Covid-19.